{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Number of serious adverse events per cohort","groups":[{"description":"0.015 mg/kg/dose of ALT-801","id":"OG000","title":"ALT-801 0.015 mg/kg/Dose"},{"description":"0.040 mg/kg/dose of ALT-801","id":"OG001","title":"ALT-801 0.040 mg/kg/Dose"},{"description":"0.080 mg/kg/dose of ALT-801","id":"OG002","title":"ALT-801 0.080 mg/kg/Dose"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 months","title":"The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies","type":"PRIMARY","unitOfMeasure":"Events"}